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Introduction
Dysregulation of the stress hormone system in depression is one 
of the most robust findings in the landscape of biological psychia-
try research (Holsboer, 2000). Hypothalamic–pituitary–adrenal 
(HPA) axis dysfunction and abnormalities in the serotonergic 
system could be connected to mood disorders and suicidal 
behaviour (Pompili et al., 2010). Regeneration of the HPA-
system is regarded as a prerequisite for obtaining a stable remis-
sion following treatment with antidepressants (Holsboer and 
Barden, 1996; Papiol et al., 2007). The FKBP5-gene influences 
the function of the HPA-system by modulating the sensitivity of 
the glucocorticoid receptor (GR). Elevated levels of FKBP5 lead 
to a decreased GR sensitivity resulting in decreased feedback 
sensitivity of the system (Vermeer et al., 2003). Several func-
tional polymorphisms have been described for the FKBP5 gene. 
TT-carriers of the polymorphism rs1360780 in the FKBP5 gene 
presented FKBP5 levels which were twice as high as C-allele 
carriers in vitro (Binder et al., 2004). Previous studies have 
demonstrated a significantly higher likelihood of response to 
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Abstract
Objective: The FKBP5-gene influences the HPA-system by modulating the sensitivity of the glucocorticoid receptor (GR). The polymorphism rs1360780 
has been associated with response in studies with heterogeneous antidepressant treatment. In contrast, several antidepressant studies with 
standardized antidepressant treatment could not detect this effect. We therefore compared patients with standardized vs naturalistic antidepressant 
treatment to (a) investigate a possible interaction between FKBP5-genotype and treatment mode and (b) replicate the effect of the FKBP5-genotype 
on antidepressant treatment outcome.
Methods: A total of 298 major depressive disorder (MDD) inpatients from the multicentred German project and the Zurich Algorithm Project were 
genotyped for their FKBP5 status. Patients were treated as usual (n=127) or according to a standardized algorithm (n=171). Main outcome criteria was 
remission (Hamilton Depression Rating Scale-21<10).
Results: We detected an interaction of treatment as usual (TAU) treatment and C-allele with the worst outcome for patients combining those two 
factors (HR=0.46; p=0.000). Even though C-allele patients did better when treated in the structured, stepwise treatment algorithm (SSTR) group, we 
still could confirm the influence of the FKBP5-genotype in the whole sample (HR=0.52; p=0.01).
Conclusions: This is the first study to show an interaction between a genetic polymorphism and treatment mode. Patients with the C-allele of the 
rs1360780 polymorphism seem to benefit from a standardized antidepressant treatment.
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antidepressant treatment for TT-homozygotes (Binder et al., 
2004) respective T-allele carriers (Kirchheiner et al., 2008). 
Indeed, a recent meta-analysis confirmed a small advantage of 
T-allele carriers in a stratified analysis of patients of Central 
European origin (Niitsu et al., 2013). In contrast to these findings, 
however, a handful of studies have failed to support the hypothe-
sis of the influence of rs1360780 on antidepressant response 
(Lekman et al., 2008; Papiol et al., 2007; Sarginson et al., 2010; 
Tsai et al., 2007). Those studies supporting the hypothesis and 
those rejecting it differed regarding the implementation of natu-
ralistic vs standardized antidepressant treatment The supportive 
studies were naturalistic in their design; using a variety of antide-
pressant agents and combination therapies whereas the negative 
studies used a standardized selective serotonin reuptake inhibitor 
(SSRI) monotherapy. In summary, Table 1 gives an overview of 
all relevant studies on the association of the rs1360780 and treat-
ment outcome. The German Algorithm Project Phase 3 (GAP3) as 
well as the Zurich algorithm-based step-by-step plan described in 
this report both evaluated a structured, stepwise treatment regime 
(SSTR) using different subsequent treatment strategies in inpa-
tients with depression. The objective of these studies was to prove 
superiority of a highly-standardized algorithm-based treatment 
over treatment as usual (TAU) (Adli et al., unpublished).
Therefore, we used treatment data from these projects to 
investigate the following main questions:
1. Is there an interaction of the polymorphism in the FKBP5 
gene with naturalistic vs standardized treatment?
2. Is there an effect of the polymorphism in the FKBP5 
gene on antidepressant response in our total sample tak-
ing into account the whole treatment process?
Patients and methods
Sample
The total sample consisted of 298 inpatients of Central European 
origin with a major depressive disorder (MDD) who were 
recruited from the German Competence Network on Depression/
German Algorithm Project (GAP3) (Adli et al., 2003; Seemüller 
et al., 2010) and the Zurich Algorithm Project (Montani et al., 
2007). Of 593 patients admitted with a depressive syndrome to 
one of the participating hospitals between 2000–2005, 475 were 
enrolled in the GAP3 and Zurich Algorithm Project of whom 
429 were eligible for further analysis:. Pharmacogenetics anal-
ysis was conducted only if an additional informed consent 
(additional to the clinical study) was given. As a consequence, 
pharmacogenetics analysis was conducted with 298 out of 429 
(69.6%) patients. Within the German Competence Network on 
Depression, the GAP3 compared a SSTR against treatment as 
usual (TAU). The study was run across multiple psychiatric set-
tings (six academic and three non-academic psychiatric hospi-
tals) (Adli et al., 2003). The Zurich study was the Swiss 
equivalent to GAP3, and given its clear correspondence to 
GAP3 in its implementation and therapeutic goals (Montani 
et al., 2007) it was included in the research to increase the 
study’s sample size. Both studies aimed at evaluating the bene-
fits of algorithm-guided treatment of depression compared to 
TAU (Adli et al., 2006). To allow inclusion of representative 
clinical populations the following inclusion criteria were 
applied: a major depressive episode according to DSM-IV 
(American Psychiatric Association, 2000) criteria, and a Hamilton 
Depression Rating Scale (HDRS-21) score ⩾15. Age at inclusion 
was 18–70 years. Additionally, written informed consent had to be 
obtained, after the procedure had been fully explained. Exclusion 
criteria were: diagnosis of bipolar disorder; depression caused by 
other medical conditions; currently being pregnant or breast-
feeding; any other prior antidepressant treatment that could not 
be discontinued; or acute and severe suicidality. Other axis I or II 
disorders were allowed if they were not the primary diagnosis. All 
intervention study arms in SSTR initially involved antidepressant 
monotherapy. All patients admitted to either of the participating 
centres were systematically assessed for eligibility and rand-
omized to the SSTR or TAU group. The SSTR group (n=171) was 
treated according to a fixed algorithm starting with an antidepres-
sant monotherapy. Within the three SSTR groups, all participants 
began with any one of four different antidepressants chosen to 
represent common pharmacological classes registered in Germany 
at the time of the protocol initiation. Allowed antidepressants 
were venlafaxine (SNRI, 225 mg/day), sertraline (SSRI, 100 mg/
day), amitriptyline (TCA, 150 mg/day) or reboxetine (noradrena-
line reuptake inhibitor (NARI), 8 mg/day), representing different 
antidepressant classes. Treating physicians could choose between 
those four medications, but had to maintain the dosage for at least 
four weeks, in cases of partial response for six weeks. In cases of 
non-response to monotherapy, patients continued with the second-
step strategy according to initial randomization: augmentation 
with lithium, dose escalation, or change of the antidepressant. In 
cases of continued failure to response to treatment, patients pro-
gressed to the next step in the algorithm after a given time period 
until electro convulsive therapy (ECT). The TAU group (n=127) 
was treated naturalistically as described elsewhere (Adli et al., 
2003), but underdosage of antidepressants was prohibited. The 
institutional local review boards approved the study design in 
all study centres. Trial Registration: http://www.germanctr.de/ 
Identifier: DRKS00000161.
Procedure
Treatment response was assessed using the HDRS-21 at baseline 
and again every two weeks during treatment. Patients were rated 
by independent study investigators who were uninvolved in the 
clinical management of patients and who were blinded to phar-
macogenetic analysis. In the case of non-improvement after four 
weeks of treatment (indicated by HDRS-21 reduction <30%), 
patients progressed to the next step of the algorithm. In case of 
partial response (HRDS-21 reduction of 30–50%), the current 
strategy was prolonged for further two weeks. Therefore, the 
maximum length of time for antidepressant monotherapy was six 
weeks. Remission was defined as achieving a score <10 on the 
HDRS-21. Across the team of study investigators, inter-rater reli-
ability on the HDRS was assessed at frequent training sessions.
Study staff and patients were masked to the randomization 
code until inclusion assessment was finished. A systematic inter-
view captured baseline clinical and socio-demographic features 
of the sample. Clinical diagnoses were confirmed with the 
Structured Clinical Interview for DSM-IV (SCID-I). Treatment 
outcome was assessed every two weeks (±three days) by non-
masked research staff who were uninvolved in treatment. The 
primary outcome based on the HRDS-21 was time to remission 
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(nine or less on the HAMD-21). After the completion of the 
inclusion assessment, patients, physicians and outcome assessors 
were not blinded to the treatment allocation.
For the present study, two different treatment periods were 
analysed according to the algorithm: The first period corre-
sponded to the duration of antidepressant monotherapy in the 
algorithm arms, and could last up to six weeks. The second analy-
sis reflects the whole treatment process from inclusion until end 
of study, i.e. up to a maximum of 14 weeks. The end-point of the 
study was remission or drop-out due to violation of the algorithm 
protocol, discharge from hospital or withdrawal of consent.
Statistical analysis
Statistical analysis was performed using SPSS 19.0. Descriptive 
statistics were performed to describe demographic and clinical 
characteristics of the study sample. Group comparisons were per-
formed using the χ2 test for categorical variables, the univariate 
analysis of variance (ANOVA) for continuous variables and the 
independent t-test for the comparison of two groups. The Hardy-
Weinberg equilibrium was tested with the χ2 test. The central sta-
tistical method used was the Cox regression survival analysis 
which facilitated the inclusion of censored cases. Calculations 
were completed using the forward LR method. In addition to our 
primary independent variable genotype, categorical covariates 
controlled for included study centre, treatment mode (standard-
ized vs naturalistic), gender, psychotic symptoms and severity. 
Continuous covariates entered into the analyses included age and 
HDRS-21 baseline. For each observation period, all 298 patients 
were entered into the analysis, during which time weekly patient 
remissions or drop outs were registered in the dataset.
To examine the interaction between genotype and treat-
ment mode, the product term genotype×treatment mode was 
included in the Cox regression analysis after including geno-
type and treatment mode individually: genotype+treatment 
mode+genotype×treatment mode.
Other exploratory analyses were performed to investigate the 
effects of different treatment strategies including class of antide-
pressants, number of treatment strategies and number of psycho-
tropic medications. For both interaction analyses, the genotype 
variable was pooled in T/T vs C-allele carriers. For all analyses, 
a two-tailed p value less than 0.05 was used as indicator for sta-
tistical significance.
Genotyping
For genotyping the rs1360780 variants in the FKBP5 gene the 
RealTime PCR method (TaqMan) was applied according to the 
protocol described by Kirchheiner et al. (2008).
Results
The total sample size comprised 298 patients, 187 women and 
111 men, who had been genotyped for the FKBP5 rs1360780 
variants. Genotype frequencies as well as distribution of demo-
graphic and clinical data are given in Table 2. No significant dif-
ferences were detected between the genotypes. Likewise no 
significant differences were found between the two treatment 
modes (SSTR vs TAU) concerning demographic and baseline 
clinical characteristics. There was a trend for shorter treatment 
duration in TT genotype patients reaching significance when 
C-allele carriers were pooled. Allele frequencies were in the 
Hardy-Weinberg equilibrium. Antidepressant substance classes 
were registered for 278 patients and did not differ significantly 
between genotypes. Comparing treatment factors between SSTR 
and TAU revealed significant differences for treatment duration, 
Table 1. FKBP5 rs1360780 and antidepressant response: research overview. 
Authors Sample Ethnicity Antidepressant treatment Main results for FKBP5 rs1360780
Binder et al., 2004 294 (MDD/DYS/BP) 
inpatients
Central European origin Naturalistic: heterogeneous/
combinations 2 and 5 weeks
Better and faster response for 
TT-genotype
Papiol et al., 2007 159 MDD outpatients Spanish Citalopram monotherapy for 
up to 12 weeks
No association
Tsai et al., 2007 125 MDD/DYS Taiwanese Fluoxetine monotherapy 4 
weeks
No association
Kirchheiner et al., 2008 179 MDD/BP inpatients Central European origin Naturalistic: heterogeneous/
combinations 3 weeks
Better response in T-allele carriers; 
worst response in CC-genotype 
combination therapy patients
Lekman et al., 2008 1809 (1256 subsample) 
outpatients
Mixed non-Hispanic 
White
Citalopram monotherapy 14 
weeks
No association in whole sample; 
trend for higher remission rates in 
TT non-Hispanic White
Sarginson et al., 2010 246 MDD (geriatric) 
outpatients
20 mixed 226 non-
Hispanic white
Paroxetine or mirtazapine 
monotherapy 8 weeks
No association
Horstmann et al., 2010 374 MDD inpatients Central European origin Naturalistic: heterogeneous/
combination 5 weeks
Gene x Gene interaction with best 
outcome for TT-genotype x GRIK4 
GG-genotype
Niitsu et al., 2013, 
meta-analysis
2194 (1405 subsample 
with Central European 
Origin)
Mixed Meta-analysis No association in whole sample; 
better response for T-allele 
carriers in Central Europeans
MDD: major depressive disorder; BP: bipolar disorder; DYS: dysthymia.
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the number of prescribed psychotropic medications, number of 
applied treatment strategies and the distribution of the prescribed 
antidepressant substance classes in both treatment modes (see 
Table 2). Mean duration of the current depressive episode was 22 
weeks (standard deviation (SD) 39.8) for the whole sample with 
a duration of 20.9 weeks (SD 43.9, n=146) in the SSTR group 
and 23.8 weeks (SD 32.7, n=90) in the TAU group (ANOVA; 
n.s.). Patients in the SSTR group had a shorter stay in the study, 
had fewer psychotropic medications and fewer changes of treat-
ment strategy. Antidepressant monotherapy with SSRI or selec-
tive serotonin/noradrenaline reuptake inhibitor (SSNRI) were 
found much more often in SSTR group while TAU patients 
were treated more frequently with antidepressant combinations. 
These findings contrast to the fact that treatment groups did not 
differ regarding depression severity at baseline measured by 
HRDS-21 score or number of prior depressive episodes (see 
Table 2). Overall remission rate was 39.9% after the first six 
weeks of treatment and increased to 54.7% at the end of the 
study. The steps to monotherapy, lithium augmentation and 
monoaminoxidase (MAO) inhibitors resulted in high remission 
rates or significant clinical improvement leading to hospital 
discharge. Consequently, ECT was not applied during the trial. 
Remission rates were significantly different between both treat-
ment modes with 66.1% for SSTR and only 39.3% for TAU (χ2; 
p<0.001). Remission rates for the FKBP5 genotypes differed sig-
nificantly after the first treatment step (TT 60.9% vs CT/C/C 
38.2%; χ2; p=0.03) but not after the entire treatment process (TT 
69.6% vs CT/CC 53.5%; χ2; p n.s.). Interestingly, remission rates 
for CC/CT allele carriers were significantly higher in SSTR com-
pared to CC/CT patients in TAU (64.4% SSTR vs 38.8% TAU; 
χ2; p<0.001), but not in TT-genotype patients, supporting the 
hypothesized interaction between FKBP5 genotype and treat-
ment mode.
Interaction between genotype and treatment 
mode
The main study objective was to examine the potential interac-
tion between genotype and treatment mode with regard to the 
treatment outcome across the entire study period. Treatment 
mode had a significant influence on treatment outcome in C-allele 
Table 2. Clinical and sociodemographic characteristics.
n=298 SSTR (n=171) TAU (n=127) Statistics
 TT n=11 CT n=68 CC n=92 TT n=12 CT n=52 CC n=63 SSTR vs TAU
Gender 298 χ2 test n.s.
Female 187 6 40 64 9 30 38
Male 111 5 28 28 3 22 25
Severity of 
depressive syndrome
298 χ2 test n.s.
Light 4 0 1 1 0 0 2
Moderate 85 3 25 25 4 15 13
Severe 185 7 38 61 8 30 41
With psychotic 
symptoms
24 1 4 5 0 7 7
Age (years) 298 39.91 (9.07) 45.79 (12.32) 45.26 (12.67) 43.08 (10.88) 41.81 (12.07) 44.56 (11.33) ANOVA n.s.
Number of prior 
episodes
234 0.86 (0.9) 1.52 (1.94) 1.34 (2.53) 2.91 (4.74) 1.7 (2.57) 1.85 (2.46) ANOVA n.s.
HRDS baseline 298 24.27 (4.56) 25.12 (5.06) 25.14 (5.59) 23.83 (6.48) 23.87 (4.78) 26.75 (6.68) ANOVA n.s.
Duration in study 
(weeks)
298 4.55 (1.75) 5.66 (2.84) 5.26 (3.23) 4.17 (3.13) 6.54 (3.88) 6.25 (4.07) ANOVA p<0.05  
(TT vs CC+CT) p<0.05
Class of ADs 278 χ2 test p<0.001
SSNRI 103 6 32 44 1 9 11  
SSRI 55 2 18 18 1 9 7  
Tricyclic AD 35 1 9 12 2 2 9  
NaSSA 24 1 1 6 2 8 6  
NARI 9 0 2 5 0 1 1  
MAO inhibitors 3 0 0 0 0 1 2  
AD combinations 54 0 2 6 5 17 24  
Number of 
psychotropic 
medications
278 1.30 (0.48) 1.44 (0.85) 1.80 (1.24) 1.73 (0.9) 2.89 (1.81) 2.45 (1.41) ANOVA p<0.001
Number of 
treatment strategies
278 1.20 (0.42) 1.42 (0.87) 1.71 (1.13) 1.55 (0.82) 2.49 (1.31) 2.02 (1.13) ANOVA p<0.001
AD: antidepressant; ANOVA: analysis of variance; HRDS: Hamilton-Rating-Depression-Scale; MAO-inhibitors: monoaminoxidase inhibitors (tranylcypromine, moclobemide); 
NARI: noradrenaline reuptake inhibitor; NaSSA: noradrenergic and specific serotonergic antidepressant (mirtazapine, mianserine); SSNRI: selective serotonin/noradrena-
line reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; TAU: treatment as usual.
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carriers but not in TT-homozygous patients. We observed a sig-
nificant interaction in terms of a synergistic effect between natu-
ralistic treatment (TAU) and the C-allele of the FKBP5 gene. 
TAU patients carrying the C-allele showed the least effective 
treatment outcome. The product variable indicating the interac-
tion effect was significant for remission (p<0.001; Hazard Ratio 
(HR)=0.46); genotype and treatment mode both lost their respec-
tive significances in the interaction analysis. These findings sug-
gest a mutual potentiating effect of naturalistic treatment and 
the C-allele. No synergistic effect of standardized treatment and 
TT-genotype was found.
To illustrate the interaction effect, we conducted separate sur-
vival analyses for both treatment modes (see Figure 1 (a)-(c)): In 
the SSTR group, the FKBP5 genotype did not contribute signifi-
cantly to treatment outcome whereas in the TAU group a large 
difference between CC/CT and TT allele carriers could be shown 
(HR 0.46; p<0.05).
We additionally conducted an exploratory analysis on which 
of the treatment factors might have led to the unfavourable out-
come for TAU/C-allele patients. This entailed the inclusion of the 
significantly different treatment factors (i.e. number of prescribed 
psychotropic medications, number of treatment strategies and 
antidepressant substance classes) into our cox regression model 
together with the C- allele genotype. Two out of these three fac-
tors emerged as significant contributors: Patients with less than 3 
prescribed psychotropic medications (HR 4.5; p<0.001) and 2 
treatment changes at the most (HR 4.1; p<0.001) yielded the best 
treatment outcome. Lastly, no interaction between genotype and 
substance classes with regard to the treatment outcome was found. 
This suggests that the influence of the genotype on treatment 
Figure 1. Cox regression survival analysis for FKBP5 genotype (all other factors kept constant):
in (a) SSTR; (b) treatment as usual (TAU); and (c) in the whole sample.
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outcome does not differ significantly across different antidepres-
sants. Study centre did not influence outcome in our sample.
Influence of genotype on remission in the 
whole sample
Regarding the second main objective of the study we found a 
significant influence of genotype on remission during the first six 
weeks (antidepressant monotherapy in SSTR) and over the whole 
observation period. After up to six weeks of antidepressant treat-
ment we already detected a significant better outcome for 
TT-allele patients (HR=1.89; p<0.03). For the whole treatment 
process of up to 12 weeks, we confirmed the findings of other 
previous studies involving patients of Central European origin. 
We observed a higher probability of achieving remission in 
TT-genotype, while CC- and CT-genotype patients were less 
likely to achieve remission (HR=0.52; p=0.01). Besides the 
FKBP5 genotype, only baseline depression scores (HR=0.05; 
p<0.01) and treatment mode (HR=2.0; p<0.01) prevailed as sig-
nificant contributors for achieving remission.
Discussion
To the best of our knowledge, the present study reflects the first 
research to demonstrate a significant interaction between the 
FKBP5 genotype at rs1360780 and treatment mode in a sample of 
depressed inpatients of Central European origin. It is also the first 
study to examine the association of the polymorphism with remis-
sion during an entire multi-step treatment process over a longer 
period of time comprising different antidepressant strategies. We 
successfully showed that the influence of genotype persists over a 
long treatment process when applying different antidepressant 
strategies. C-allele carriers had a significantly worse outcome 
when treated naturalistically and showed improved remission 
rates when treated according to a systematic treatment algorithm. 
In contrast, TT-allele carriers showed a superior treatment 
response across both SSTR and TAU treatment conditions. 
Combining our algorithm and the TAU group, we were able to 
confirm the results of pre-existing studies and a recent meta-anal-
ysis of a more favourable treatment outcome in T-allele patients 
(Binder et al., 2004; Horstman et al., 2010; Kirchheiner et al., 
2008; Niitsu et al., 2013). Contradictory findings exist (Lekman 
et al., 2008; Sarginson et al., 2010; Tsai et al., 2007) and in addi-
tion to the risk of non-replication of single nucleotide polymor-
phism association studies, a number of reasons may be responsible 
for inconsistencies in the body of research to date: Firstly, patient 
ethnicity varied with Asian (Tsai et al., 2007), Spanish (Papiol 
et al., 2007), mixed Afro- and non-Hispanic white-American 
(Lekman et al., 2008; Sarginson et al., 2010) and Central European 
patients (Binder et al., 2004; Horstmann et al., 2010; Kirchheiner 
et al., 2010) being analysed for their FKBP5 status. Therefore, the 
meta-analysis by Niitsu et al. (2013) stratified for ethnicity and 
could only confirm a small but significant superior response for 
T-allele carriers in patients of Central European origin. Secondly, 
studies were different regarding important clinical variables such 
as depression severity, diagnosis, duration of treatment and choice 
of the antidepressant strategy. While the largest study by Lekman 
et al. (2008), as part of the Star*d project, involved outpatients 
exclusively, Binder et al. (2004), Kirchheiner et al. (2010) and 
Horstmann et al. (2010) and the present study included inpatients 
only. In some studies, patients with bipolar depression or dysthy-
mia were included; others only integrated patients with unipolar 
depression and a severity cut-off. Furthermore, our data point to 
another important difference potentially relevant for inconsisten-
cies of the published studies on the FKBP5 influence on antide-
pressant response: All of the studies lacking evidence for the 
influence of genotype used a homogenous treatment design, 
mostly with SSRI monotherapy as the single exclusive treatment 
(Lekman et al., 2008; Papiol et al., 2007; Tsai et al., 2007). Only 
in the hypothesis-rejecting study by Sarginson et al. (2010), were 
both mirtazapine and the SSRI paroxetine respectively studied as 
monotherapeutic agents. In the hypothesis-supporting studies, 
treatment was allowed to be naturalistic with various antidepres-
sants and treatment combinations. Given that our data facilitated 
the direct comparison of the effects of naturalistic vs structured 
antidepressant treatment; we may have identified a possible 
explanation for this effect.
We found a synergistic effect between TAU and CT- resp. 
CC-genotype implicating that carriers of the ‘unfavourable’ 
C-allele may particularly benefit from SSTR. This standardized 
treatment may compensate for their disadvantage in particular by 
potentially engaging those patients in prolonged antidepressant 
monotherapy. For the T/T-genotype, the treatment mode seems to 
be less crucial.
In essence, SSTR differed from TAU by exemplifying clear, 
sequential therapy guidelines and by diligently evaluating treat-
ment response at critical decision points as the basis for a stand-
ardized treatment decision process (Adli et al., 2003; Bauer et al., 
2009). By its structured treatment protocol, SSTR prevents pre-
mature treatment changes, polypharmacy and unstructured appli-
cation of treatment strategies. Patients with the unfavourable 
FKBP5 genotype seem to benefit particularly from this treatment 
optimization.
The underlying biological mechanisms of what precisely 
characterizes the difference in treatment response between 
the FKBP5 genotypes are still uncertain. FKBP-5 acts as a 
co-chaperone that modulates sensitivity of the GR (Zannas 
et al., 2015). In particular, in vitro experiments have shown 
that FKBP5 reduces interaction of the GR complex with the 
transport protein dynein, delays nuclear translocation of the 
GR, and decreases GR-dependent transcriptional activity 
(Wochnik et al., 2005) By modulating the HPA axis through 
GR signalling, FKBP5 seems to play an important relay func-
tion that is highly relevant for many patients with affective 
disorders. A number of studies could demonstrate a clear asso-
ciation of FKBP5 status with clinical markers of depression: 
After eight weeks of escitalopram or nortriptyline monother-
apy, levels of mRNA of FKBP5 were significantly reduced in 
responders but not in non-responders (Cattaneo et al., 2013). 
Binder described a stronger dysregulation of the HPA-system 
in T-allele – compared to C-allele carriers – during a depres-
sive episode (Binder, 2009). Due to a tighter interplay of 
FKBP5-expression and cortisol-levels in TT-carriers, their 
HPA-regulation seems to be less stable and more sensitive to 
environmental influences (Binder et al., 2004; Klengel et al., 
2013). This might explain the superior response in TT-patients 
because antidepressants may more easily interfere with HPA-
system regulation as it has been shown that antidepressants 
reduce Corticotropin-releasing hormone and cortisol levels 
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(Ising et al., 2007). The interplay of cortisol levels and FKBP5 
expression in TT-patients might lead to a more rapid down-
regulation of FKBP5 due to a reduction of cortisol levels dur-
ing antidepressant treatment and thus to higher sensitivity of 
GRs. In both healthy and depressed C-allele carriers the corti-
sol-induced FKBP5-expression seems to be less pronounced. 
Their HPA-system seems to be less reactive to environmental 
influences. The proportionally higher HPA-dysregulation dur-
ing depression and the lower correlation of cortisol and FKBP5 
levels in C-allele carriers might contribute to explain their 
inclination to benefit from a standardized treatment. These fac-
tors lead to a slower and reduced interference of the HPA-
system with antidepressant drugs. This would increase the 
importance of exhausting the chosen treatment strategy in 
C-allele carriers. Therefore, these patients seem particularly 
responsive to the application of a structured procedure. The 
lower probability of remission during the whole study period 
in C-allele carriers suggests a higher tendency to treatment 
resistance in those patients, possibly also due to the described 
biochemical mechanisms.
The results of our study emphasize the importance of a struc-
tured and algorithm-guided antidepressant treatment, especially as 
patients disadvantaged because of their genotype benefit from a 
structured treatment. A standardized procedure may allow higher 
remission rates achieved in a shorter time with less medication and 
changes of treatment strategies. Additionally, a genetic disadvan-
tage can be compensated by algorithm-guided treatment. The find-
ings suggest that a standardized, quality-controlled treatment may 
to an extent compensate for a ‘genetic disadvantage’ in C-allele 
carriers. Hence, the treatment results for C-allele carriers approach 
to those of TT-carriers in algorithm-guided treatment. This might 
explain why the influence of this genotype on treatment response 
could not be replicated in all studies. As mentioned above, the 
negative studies with regard to FKBP5 genotype had a strictly 
homogenous treatment design with a predefined (mostly SSRI-
based) monotherapy (similar to our own SSTR group), whereas the 
studies in support of the influence of genotype had a heterogene-
ous treatment design (as was the case in our TAU group).
Limitations
The first limitation of this study is the relatively small sample 
size for a pharmacogenetic study. Secondly, although the deci-
sion to recruit patients for this study from two different projects 
for this study was justifiable given their identical operations and 
characteristics, it is a source of heterogeneity. On the one hand, 
the inclusion of patients treated with different substance classes, 
partly naturalistically and partly standardized, led to heterogene-
ity in participants` medical treatment. On the other hand, the con-
sideration of all patients made it possible to obtain a sufficiently 
large sample size and thereby allowed further analysis concern-
ing the treatment mode. In relation to the main objective of the 
study, the explanatory power of an interaction between genotype 
and treatment mode is restricted due to the low percentage of 
T/T-carriers: Only 7.72% of the whole sample were T/T-carriers. 
Besides the FKBP5 gene, other sources of genetic heterogeneity 
could be examined regarding their influence on treatment in anti-
depressant therapy. Possible candidate genes could be the 
SLC6A4, HTR2A, BDNF, GNB3, ABCD1 and cytochrome p450 
genes (Fabbri and Serretti, 2015).
Our intentions with these research questions were purely 
exploratory in nature and as such may be considered preliminary 
and requiring further analysis in future. Future studies are par-
ticularly important to rule out the possibility that the independ-
ence of the treatment mode in TT-patients is not in fact due to a 
randomly distribution; this was not possible in our sample.
Conclusion
The influence of the FKBP5 polymorphism rs1360780 was suc-
cessfully replicated in the present study suggesting a predictive 
value of this single nucleotide polymorphism for antidepressant 
treatment outcome in moderate to severely depressed inpatients 
of Central European origin. The polymorphism might contribute 
to more individually-tailored therapeutic choices in the future. 
As the effect of genotype does not seem to differ considerably 
across substance classes, it is currently not possible to draw clear 
conclusions concerning the choice of an antidepressant. C-allele 
carriers particularly seem to benefit from a structured algorithm-
guided treatment which compensates their ‘genetic disadvantage’. 
Better treatment outcomes in TT-patients seem to be mostly inde-
pendent of the applied treatment mode.
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